title: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.
abstract: BACKGROUND
  Sirolimus (rapamycin) is a potent immunosuppressant with a mechanism of action different from cyclosporine (CsA) or tacrolimus.
  
  
  METHODS
  In 11 European centers, first cadaveric renal allograft recipients were randomized to CsA (n=42) or sirolimus (n=41). Dosing of these agents was concentration-controlled and open-labeled. All patients received corticosteroids and azathioprine.
  
  
  RESULTS
  At 12 months, graft survival (98% sirolimus vs. 90% CsA), patient survival (100% vs. 98%), and incidence of biopsy-confirmed acute rejection (41% vs. 38%) were similar. Serum creatinine was lower with sirolimus, significantly (P< or =0.05) so at 3 and 4 months, and serum uric acid and magnesium were normal. Laboratory abnormalities reported significantly more often with sirolimus included hypertriglyceridemia (51% vs. 12%), hypercholesterolemia (44% vs. 14%), thrombocytopenia (37% vs. 0%), leukopenia (39% vs. 14%), and, of lesser importance, increased liver enzymes and hypokalemia. These abnormalities improved 2 months after transplantation when the sirolimus target trough level was lowered from 30 to 15 ng/ml. Occurrence of cytomegalovirus was comparable (14% vs. 12%); incidences of herpes simplex (24% vs. 10%, P=0.08) and pneumonia (17% vs. 2%, P=0.03) were higher with sirolimus. No gingival hyperplasia was seen with sirolimus, tremor was rare, and hypertension was less frequent (17% vs. 33%). Two malignancies were observed with CsA and none with sirolimus.
  
  
  CONCLUSIONS
  Results at 12 months suggest that sirolimus can be used as base therapy in the prophylaxis of acute renal transplant rejection, and has a safety profile that differs from CsA.
authors.affiliation: Huddinge Hospital, Stockholm, Sweden.
authors.forename: C G
authors.initials: CG
authors.lastname: Groth
authors.forename: L
authors.initials: L
authors.lastname: Bäckman
authors.forename: J M
authors.initials: JM
authors.lastname: Morales
authors.forename: R
authors.initials: R
authors.lastname: Calne
authors.forename: H
authors.initials: H
authors.lastname: Kreis
authors.forename: P
authors.initials: P
authors.lastname: Lang
authors.forename: J L
authors.initials: JL
authors.lastname: Touraine
authors.forename: K
authors.initials: K
authors.lastname: Claesson
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
authors.forename: D
authors.initials: D
authors.lastname: Durand
authors.forename: L
authors.initials: L
authors.lastname: Wramner
authors.forename: C
authors.initials: C
authors.lastname: Brattström
authors.forename: B
authors.initials: B
authors.lastname: Charpentier
mesh_terms: D000328:Adult; D000368:Aged; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007668:Kidney / Q000503:physiopathology; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010352:Patient Dropouts; D010865:Pilot Projects; D020123:Sirolimus / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D020123:Sirolimus